CO2022001413A2 - Métodos para preparar análogos de incretina - Google Patents
Métodos para preparar análogos de incretinaInfo
- Publication number
- CO2022001413A2 CO2022001413A2 CONC2022/0001413A CO2022001413A CO2022001413A2 CO 2022001413 A2 CO2022001413 A2 CO 2022001413A2 CO 2022001413 A CO2022001413 A CO 2022001413A CO 2022001413 A2 CO2022001413 A2 CO 2022001413A2
- Authority
- CO
- Colombia
- Prior art keywords
- preparing
- methods
- incretin analogs
- incretin
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen compuestos intermediarios para preparar análogos de incretina o sales farmacéuticamente aceptables de estos. Además, se describen métodos para preparar análogos de incretina mediante el acoplamiento de dos a cuatro de los compuestos intermediarios de la presente descripción mediante síntesis en fase híbrida sólida líquida o unión química nativa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962888756P | 2019-08-19 | 2019-08-19 | |
PCT/US2020/046778 WO2021034815A1 (en) | 2019-08-19 | 2020-08-18 | Methods of making incretin analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022001413A2 true CO2022001413A2 (es) | 2022-03-18 |
Family
ID=72322545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0001413A CO2022001413A2 (es) | 2019-08-19 | 2022-02-11 | Métodos para preparar análogos de incretina |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220411461A1 (es) |
EP (1) | EP4017866A1 (es) |
JP (1) | JP2022545200A (es) |
KR (1) | KR20220035199A (es) |
CN (1) | CN114269775A (es) |
AU (1) | AU2020334993B2 (es) |
BR (1) | BR112022001081A2 (es) |
CA (1) | CA3148347A1 (es) |
CL (1) | CL2022000374A1 (es) |
CO (1) | CO2022001413A2 (es) |
EC (1) | ECSP22013340A (es) |
IL (1) | IL289957A (es) |
MX (1) | MX2022002115A (es) |
PE (1) | PE20221049A1 (es) |
WO (1) | WO2021034815A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023008330A (es) | 2021-01-20 | 2024-01-18 | Viking Therapeutics Inc | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. |
JP2024518058A (ja) | 2021-05-07 | 2024-04-24 | イーライ リリー アンド カンパニー | 浸食性錠剤 |
TW202404996A (zh) * | 2022-04-04 | 2024-02-01 | 美商美國禮來大藥廠 | 製備glp-1/升糖素雙重促效劑之方法 |
CN115368234B (zh) * | 2022-08-19 | 2024-01-26 | 淄博矿业集团有限责任公司 | 一种索马鲁肽侧链及其中间体的合成方法 |
WO2024077149A2 (en) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides for incretin synthesis |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011006644A2 (en) * | 2009-07-15 | 2011-01-20 | Lonza Ltd | Process for the production of exenatide and of an exenatide analogue |
TR201815338T4 (tr) | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
SI3004155T1 (sl) * | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
JP2017503474A (ja) | 2013-11-06 | 2017-02-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン−glp−1−gipトリプルアゴニスト化合物 |
CN103613656B (zh) * | 2013-11-20 | 2015-03-04 | 陕西东大生化科技有限责任公司 | 一种艾塞那肽的固相片段合成方法 |
JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
EP3398961B1 (en) | 2015-12-31 | 2022-06-29 | Hanmi Pharm. Co., Ltd. | Triple activator activating glucagon, glp-1 and gip receptor |
NZ746784A (en) | 2016-03-10 | 2022-11-25 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
CN106749610A (zh) * | 2016-12-29 | 2017-05-31 | 陕西慧康生物科技有限责任公司 | 一种艾塞那肽的制备方法及其产品 |
TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
MY197569A (en) | 2018-07-23 | 2023-06-25 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
-
2020
- 2020-08-18 WO PCT/US2020/046778 patent/WO2021034815A1/en unknown
- 2020-08-18 PE PE2022000273A patent/PE20221049A1/es unknown
- 2020-08-18 AU AU2020334993A patent/AU2020334993B2/en active Active
- 2020-08-18 JP JP2022510146A patent/JP2022545200A/ja active Pending
- 2020-08-18 BR BR112022001081A patent/BR112022001081A2/pt unknown
- 2020-08-18 US US17/633,631 patent/US20220411461A1/en active Pending
- 2020-08-18 KR KR1020227005160A patent/KR20220035199A/ko active Search and Examination
- 2020-08-18 CN CN202080059063.8A patent/CN114269775A/zh active Pending
- 2020-08-18 EP EP20765144.9A patent/EP4017866A1/en active Pending
- 2020-08-18 MX MX2022002115A patent/MX2022002115A/es unknown
- 2020-08-18 CA CA3148347A patent/CA3148347A1/en active Pending
-
2022
- 2022-01-18 IL IL289957A patent/IL289957A/en unknown
- 2022-02-11 CO CONC2022/0001413A patent/CO2022001413A2/es unknown
- 2022-02-15 CL CL2022000374A patent/CL2022000374A1/es unknown
- 2022-02-18 EC ECSENADI202213340A patent/ECSP22013340A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220035199A (ko) | 2022-03-21 |
JP2022545200A (ja) | 2022-10-26 |
CA3148347A1 (en) | 2021-02-25 |
WO2021034815A1 (en) | 2021-02-25 |
ECSP22013340A (es) | 2022-03-31 |
AU2020334993B2 (en) | 2023-07-13 |
US20220411461A1 (en) | 2022-12-29 |
AU2020334993A1 (en) | 2022-02-24 |
EP4017866A1 (en) | 2022-06-29 |
PE20221049A1 (es) | 2022-06-30 |
BR112022001081A2 (pt) | 2022-05-24 |
IL289957A (en) | 2022-03-01 |
MX2022002115A (es) | 2022-03-17 |
CN114269775A (zh) | 2022-04-01 |
CL2022000374A1 (es) | 2022-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22013340A (es) | Métodos para preparar análogos de incretina | |
AR114631A1 (es) | Métodos e intermedios para preparar compuestos de piridina | |
AR118856A2 (es) | Compuestos terapéuticos | |
NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
CY1119731T1 (el) | Διαδικασια για την παρασκευη παραγωγων χολικου οξεος | |
GT201300207A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
CR20120460A (es) | Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales | |
UY32490A (es) | Inhibidores de beta-secretasa | |
DOP2013000221A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA | |
GT201400195A (es) | Compuestos de heterociclilo como inhibidores de mek | |
AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
DOP2014000121A (es) | Derivados de betulina | |
EA201591815A1 (ru) | Бицикло [2.2.2] кислоты - модуляторы gpr120 | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
CY1124608T1 (el) | Παραγωγα φαινυλιου ως ρυθμιστες υποδοχεα pge2 | |
CY1121147T1 (el) | Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου | |
BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
CO2017010725A2 (es) | N-[3-[(4as,5s,7as)-2-amino-5-(1,1-difluoroetil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-ciano-2-picolamida, su sal metanosulfonato y una forma cristalina hemihidrato de la sal 4-metilbencenosulfonato del mismo, composiciones que los contienen y procedimientos para su elaboración | |
CU20200047A7 (es) | Compuestos de alquinileno sustituidos como agentes anticancerígenos | |
AR090959A1 (es) | Analogos de hexadepsipeptidos como compuestos anticancerigenos | |
CL2019002967A1 (es) | Proceso para la preparación de piperazina para la síntesis de derivados de pirazinocarbazol. |